Company Overview and News
KUALA LUMPUR (July 19): The FBM KLCI pared some its gains at the midday break today and was up 0.44%, against the backdrop of higher regional markets.
PBLOF MLYBY MLYNF 7113 TPGVF 1295 3794 5014 9334 0131 TGLVY 1155 4588 3867 8613 6459 5819 MYPRY 1929
KUALA LUMPUR (July 19): The FBM KLCI rose 0.56% at mid-morning today, boosted by gains including at index-linked banking heavyweights.
PBLOF 7251 MLYNF MS.PRE MS.PRF MS.PRG MS.PRA 1295 7153 3794 2089 5014 9334 3867 6459 CSX MS 7083 MLYBY UPBMF 0170 0131 7123 1155 4588 MS.PRI MS.PRK MYPRY
KUALA LUMPUR, July 13 — Lafarge Malaysia Bhd's share price on Bursa Malaysia advanced in the early session despite its RM270 million cement supply contract for the proposed East Coast Rail Link (ECRL) project being suspended.
1800 BSMAF 3794 1818
KUALA LUMPUR: WCT Holdings Bhd , Lafarge Malaysia Bhd , Gabungan AQRS Bhd and Kumpulan Jetson Bhd are among the stocks to watch, according to JF Apex Research.
5226 9083 9679 3794
KUALA LUMPUR (July 13): The FBM KLCI is seen trending higher today, in line with the firmer overnight close at Wall Street and most global markets, and hover around the 1,690-1,700 level.
5226 6084 0026 4723 9083 9679 3794
KUALA LUMPUR (July 12): Based on corporate announcements and news flow today, companies in focus on Friday (July 13) may include: WCT, Lafarge Malaysia, Star Media Group, JAKS Resources, Gabungan AQRS, Atlan, Kumpulan Jetson, Nova MSC and SKH Consortium.
5932 5226 6084 3751 0026 4723 9083 1800 9679 3794
KUALA LUMPUR (July 12): Lafarge Malaysia Bhd's RM270 million cement supply contract for the proposed East Coast Rail Link (ECRL) project has been suspended by China Communications Construction (ECRL) Sdn Bhd, following the suspension of the project pending a government review.
1800 BSMAF 3794 1818
KUALA LUMPUR (July 5): The FBM KLCI hovered above the 1,690-level at mid-morning today, amid some choppy trade as regional markets stayed anxious.
HLFBF PBLOF MLYBY MLYNF UPBMF 1082 1295 3794 2089 1155 KLKBY 2445 3883 4863 6888 5819 AXXTF MYTEF
KUALA LUMPUR (July 2): The FBM KLCI remained subdued at mid-morning today after data showed business conditions across Malaysia’s manufacturing sector deteriorating albeit at a slower pace in June.
7052 PBLOF BATS 4162 1295 3794 2089 7077 5199 DKSHY KLKBY 3867 7206 HIPEF 5908 SPMXF UPBMF 8133 1481 5139 2445 4588 SPMXY 0026 0900 5819 DKSHF
KUALA LUMPUR (July 2): CIMB IB Researh has downgraded the Building Materials sector to “Underweight’ (from Neutral) and said cement players are worse off after the job cancellations post-GE14.
KUALA LUMPUR (July 2): The FBM KLCI got off to a subdued start for the second half of 2018 as it dipped in early trade following the release of data showing business conditions across Malaysia’s manufacturing sector deteriorating albeit at a slower pace in June.
HLFBF PBLOF 3867 1082 5681 1295 3794
Lafarge Malaysia Bhd (June 22, RM3.02) Maintain sell with a lower target price (TP) of RM2.50: Domestic cement production (which provides an indication of cement demand) remained weak as it fell 14% year-on-year (y-o-y) in the first four months of 2018 (4M18) after posting a 2% y-o-y decline in 4M17, underpinned by the subdued property market and delays in the roll-out of new infrastructure projects.
IN cities such as Kuala Lumpur where land cost is rising, space comes at a premium, leading to smaller homes being built. Whether one likes it or not, the small homes trend is a given within cities.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...